114 results
424B3
SLGL
Sol-Gel Technologies Ltd
20 May 24
Prospectus supplement
4:05pm
, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions … retirement
TOTAL NON-CURRENT ASSETS
TOTAL ASSETS
Liabilities and shareholders' equity
CURRENT LIABILITIES:
Accounts payable
Other accounts payable
6-K
EX-99.1
SLGL
Sol-Gel Technologies Ltd
20 May 24
Sol-Gel Reports First Quarter 2024 Financial Results and Provides
7:15am
in the United States, China, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political …
Funds in respect of employee rights upon retirement
TOTAL NON-CURRENT ASSETS
TOTAL ASSETS
Liabilities and shareholders' equity
CURRENT LIABILITIES
6-K
EX-99.1
SLGL
Sol-Gel Technologies Ltd
16 May 24
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to
6:15am
) loss or retirement of key executives and research scientists; (xvi) general market, political and economic conditions in the countries in which
424B3
SLGL
Sol-Gel Technologies Ltd
4 Apr 24
Prospectus supplement
9:05am
and support the use of Twyneo, Epsolay and our product candidates; and
loss or retirement of key executives and research scientists.
You should review
6-K
EX-99.1
SLGL
Sol-Gel Technologies Ltd
1 Apr 24
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to
7:15am
States, Europe or Israel; and (xv) loss or retirement of key executives and research scientists; (xvi) general market, political and economic
POS AM
fwposzjg42
20 Mar 24
Prospectus update (post-effective amendment)
4:05pm
6-K
EX-99.1
hvyuf7o1
13 Mar 24
Sol-Gel Reports Full-Year 2023 Financial Results and 2023 - Corporate Highlights and Recent Developments
8:34am
6-K
EX-99.1
ykmp2q52
30 Nov 23
Current report (foreign)
7:10am
424B3
0xxgmtn qq0
9 Nov 23
Prospectus supplement
3:41pm
6-K
EX-99.1
pgwcmf6g
9 Nov 23
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:15am
424B3
ga1ych834pxub5
10 Aug 23
Prospectus supplement
7:20am
6-K
EX-99.2
v13bhbwd763 eye
10 Aug 23
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
EX-99.1
4f3t8om bayf7
10 Aug 23
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:10am
6-K
EX-99.1
ltgcwj
6 Jun 23
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to
7:15am
424B3
a8v5vcbn54f64231buzs
12 May 23
Prospectus supplement
9:15am
6-K
EX-99.1
8p2iajnsyv tor1k3
12 May 23
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides
12:00am
6-K
EX-99.1
r3scp ojdrg50r
21 Nov 22
Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
4:42pm